Genitope Corporation to Host Conference Call to Discuss Initial Results of Phase 3 Clinical TrialFREMONT, Calif.--(BUSINESS WIRE)--Dec 20, 2007 - Genitope Corporation (NASDAQ: GTOP) announced that it will hold a conference call today at 2 p.m. PST/5 p.m. EST to discuss the initial results of its pivotal Phase 3 clinical trial examining MyVax(R) personalized immunotherapy in previously untreated follicular B-cell non-Hodgkin's lymphoma. The company intends to issue a press release after 4:00 p.m. EST today announcing the initial results of its Phase 3 clinical trial.
Conference Call Information:
Domestic callers: 866.314.4865
International callers: 617.213.8050
Webcast information: http://ir.genitope.com/
The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the call at www.fulldisclosure.com, Thomson/CCBN's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents (www.streetevents.com).
A replay of the conference call will be available beginning at 4:00 p.m. PST on December 20, 2007 through 11:59 p.m. PST on December 27, 2007. Access numbers for this replay are: 1-888-286-8010 (U.S./Canada) and 1-617-801-6888 (international). The access code for the replay is 94221341. Additionally, the webcast will be available for 30 days.
About Genitope Corporation
Genitope Corporation (Fremont, Calif.) is a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. Genitope Corporation's lead product candidate, MyVax(R) personalized immunotherapy, is a patient-specific active immunotherapy based on the unique genetic makeup of a patient's tumor and is designed to activate the patient's immune system to identify and attack cancer cells. For more information on the company, please log on to http://www.genitope.com.
Posted: December 2007